Clinical Trial Update: LOcoregional vs Systemic Therapy in Patients With BCLC Stage B HCC [Phase 2]

View source ↗

Summary

A Phase 2 trial comparing locoregional therapy versus systemic therapy for intermediate-stage hepatocellular carcinoma (BCLC stage B) has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Locoregional therapy
• Systemic therapy

Snippet

Sponsor: University of Texas Southwestern Medical Center | Conditions: Hepatocellular Carcinoma | Phase 2 | Status: TERMINATED